Nauck, Michael A.

Incretin hormones and type 2 diabetes

Nauck, M. A., & Müller, T. D. (2023) · Diabetologia

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 190

Gut hormones and diabetes mellitus

Creutzfeldt, W., & Nauck, M. (1992) · Diabetes/Metabolism Reviews

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 176

Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial

Buse, J. B., Bain, S. C., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Pratley, R. E., Linder, M., Monk Fries, T., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 175

Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: A meta-analysis based on cardiovascular outcomes trials

Abd El Aziz, M., Cahyadi, O., Meier, J. J., Schmidt, W. E., & Nauck, M. A. (2020) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacovigilance and Adverse Drug Reactions

Cited by 160

Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide

Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2024) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementGastrointestinal motility and disorders

Cited by 157

A meta‐analysis comparing clinical effects of short‐ or long‐acting GLP ‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients

Abd El Aziz, M. S., Kahle, M., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 155

Erythromycin Antagonizes the Deceleration of Gastric Emptying by Glucagon-Like Peptide 1 and Unmasks Its Insulinotropic Effect in Healthy Subjects

Meier, J. J., Kemmeries, G., Holst, J. J., & Nauck, M. A. (2005) · Diabetes

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 146

Do GLP-1–Based Therapies Increase Cancer Risk?

Nauck, M. A., & Friedrich, N. (2013) · Diabetes Care

Diabetes Treatment and ManagementPancreatic and Hepatic Oncology Research

Cited by 145

Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD ‐2 study

Nauck, M., Frid, A., Hermansen, K., Thomsen, A. B., During, M., Shah, N., Tankova, T., Mitha, I., & Matthews, D. R. (2013) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 144

Once-daily liraglutide versus lixisenatide as add-on to metformin in type 2 diabetes: a 26-week randomized controlled clinical trial

Nauck, M., Rizzo, M., Johnson, A., Bosch-Traberg, H., Madsen, J., & Cariou, B. (2016) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 143

Direct effect of GLP-1 infusion on endogenous glucose production in humans

Seghieri, M., Rebelos, E., Gastaldelli, A., Astiarraga, B. D., Casolaro, A., Barsotti, E., Pocai, A., Nauck, M., Muscelli, E., & Ferrannini, E. (2013) · Diabetologia

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 143

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists

Urva, S., Coskun, T., Loghin, C., Cui, X., Beebe, E., O'Farrell, L., Briere, D. A., Benson, C., Nauck, M. A., & Haupt, A. (2020) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementGastrointestinal motility and disorders

Cited by 143

Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes

Nauck, M. A., El-Ouaghlidi, A., Gabrys, B., Hücking, K., Holst, J. J., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Meier, J. J. (2004) · Regulatory Peptides

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 137

Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke: Post Hoc Analysis From the LEADER Trial

Verma, S., Poulter, N. R., Bhatt, D. L., Bain, S. C., Buse, J. B., Leiter, L. A., Nauck, M. A., Pratley, R. E., Zinman, B., Ørsted, D. D., et al. (2018) · Circulation

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 127

GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits

Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 123

Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists

Gasbjerg, L. S., Bergmann, N. C., Stensen, S., Christensen, M. B., Rosenkilde, M. M., Holst, J. J., Nauck, M., & Knop, F. K. (2020) · Peptides

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 121

Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure

Marso, S. P., Baeres, F. M. M., Bain, S. C., Goldman, B., Husain, M., Nauck, M. A., Poulter, N. R., Pratley, R. E., Thomsen, A. B., & Buse, J. B. (2020) · Journal of the American College of Cardiology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 118

Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial

Verma, S., Bhatt, D. L., Bain, S. C., Buse, J. B., Mann, J. F. E., Marso, S. P., Nauck, M. A., Poulter, N. R., Pratley, R. E., Zinman, B., et al. (2018) · Circulation

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 105

The glucagon-like peptide-1 metabolite GLP-1-(9–36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans

Meier, J. J., Gethmann, A., Nauck, M. A., Götze, O., Schmitz, F., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Holst, J. J. (2006) · American Journal of Physiology-Endocrinology and Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 104

Gut hormone co-agonists for the treatment of obesity: from bench to bedside

Nogueiras, R., Nauck, M. A., & Tschöp, M. H. (2023) · Nature Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 102

Risk of pancreatitis in patients treated with incretin-based therapies

Meier, J. J., & Nauck, M. A. (2014) · Diabetologia

Diabetes Treatment and ManagementPancreatitis Pathology and Treatment

Cited by 101

GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: A randomised trial

Gögebakan, Ö., Osterhoff, M. A., Schüler, R., Pivovarova, O., Kruse, M., Seltmann, A.-C., Mosig, A. S., Rudovich, N., Nauck, M., & Pfeiffer, A. F. H. (2015) · Diabetologia

Adipokines, Inflammation, and Metabolic DiseasesAdipose Tissue and Metabolism

Cited by 95

Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective

Nauck, M. A. (1998) · Acta Diabetologica

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 94

Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial

Nauck, M. A., Jensen, T. J., Rosenkilde, C., Calanna, S., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care

Diabetes Treatment and ManagementMetabolism, Diabetes, and Cancer

Cited by 94